All In Biotech

Free tool

FAERS Monitor: Palsonify

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219070 or its brand name (Palsonify, Paltusotine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

238

Serious

36

15% of reports

Hospitalization

24

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea52
  • fatigue28
  • product dose omission issue28
  • nausea27
  • abdominal discomfort25
  • arthralgia21
  • headache21
  • abdominal pain16
  • abdominal pain upper15
  • gastrointestinal disorder14
  • off label use14
  • therapy interrupted14
  • blood glucose increased13
  • dizziness13
  • incorrect dose administered12

Reports by year received

View as table
YearReports
20252
2026236

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,921 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapy interruptedSignal1417.310.4200
gastrointestinal disorderSignal1413.88.3154
abdominal discomfortSignal2513.29.1271
product dose omission issueSignal288.45.9178
diarrhoeaSignal527.15.6276
abdominal pain upperSignal156.43.964
blood glucose increasedSignal136.13.651
abdominal painSignal166.13.864
incorrect dose administeredSignal124.62.731
arthralgiaSignal214.53.054
fatigueSignal283.22.241
nauseaSignal273.02.136
headacheSignal213.02.026
dizzinessSignal132.31.49
off label use141.40.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.